本次服贸会以"服务合作、绿色发展"为主题，汇聚了来自全球的服务贸易企业。欣悦健康展区以"居家养老四件套"为 展示主线，通过实景体验、视频解说、设备互动等多种形式，全面呈现其针对中国老年人居家养老难题的系统解决方 案。 all Bo 3890 07 t LI S ( b- Du 即 AM / Mil =11 如厕即健康筛查 P (1 x 3 B 9月10日，2025年中国国际服务贸易交易会(以下简称"服贸会")在北京首钢园隆重开幕。作为健康养老领域的创新代 表，山东欣悦健康科技有限公司携核心产品"居家养老四件套"与"万医生"健康管理生态亮相展会，引来众多观众、行 业专家及媒体驻足关注。 欣悦健康 居家养老 件章 开启健康养老 新生活 役 家庭 养老 用 医疗人户 辅具到家 8 医护 适老 ~ 照护上门 环境改造 适老环境改造，通过空间功能升级和全场景适老优化，为老人打造一个健康、安全、舒适的居家养老环境；养老辅具 到家，提供个性化辅具精准适配与全周期服务，助力维持生活自理能力，守护居家养老尊严；家庭医疗入户，以"万医 生健康管理生态"为依托，将医疗级服务延伸至家庭场景，再配合线下医疗入户服务，让老人足不出户即可 ...

Core Viewpoint - Nanjing Xinbai has faced disciplinary actions from the Shanghai Stock Exchange due to failures in timely disclosure of external guarantees and related party transactions, leading to penalties for the company and its controlling shareholder, Sanpower Group [1][2][3]. Group 1: External Guarantees - Nanjing Xinbai's subsidiary, Nanjing Xinbai Real Estate Development Co., Ltd., provided external guarantees from 2018 to 2021, amounting to 2.095 billion, 1.376 billion, 1.537 billion, and 1.949 billion respectively [1]. - Another subsidiary, Taizhou Danrui Biotechnology Co., Ltd., also provided external guarantees of 531 million and 547 million in 2019 and 2020 [1]. Group 2: Related Party Transactions - Nanjing Xinbai failed to disclose funds occupied by its controlling shareholder, Sanpower Group, which amounted to 492 million in 2017 through indirect payments [2]. - In 2017 and 2018, transactions with related parties totaled 193.35 million and involved other companies, but Nanjing Xinbai did not disclose these transactions in its annual reports [3]. Group 3: Disciplinary Actions - The Shanghai Stock Exchange issued public reprimands to Nanjing Xinbai, Sanpower Group, and several key executives for their failures in disclosure and compliance [3]. - The penalties included a fine of 4 million for Sanpower Group and 2 million for its actual controller, Yuan Yafei, along with a 10-year market ban for Yuan Yafei [5]. Group 4: Company Background - Nanjing Xinbai, established in 1952 and listed in 1993, is a major player in retail and healthcare, with its main revenue coming from the health and medical industry [4].

Core Viewpoint - Nanjing Xinjiekou Department Store Co., Ltd. (Nanjing Xinjie, 600682) faced disciplinary actions from the Shanghai Stock Exchange due to failures in timely reviewing and disclosing external guarantee matters, leading to penalties for three chairmen [1][4] Group 1: External Guarantees - Nanjing Xinjie’s subsidiary, Nanjing Xinjie Real Estate Development Co., Ltd., had external guarantees from 2018 to 2021 amounting to 2.095 billion, 1.376 billion, 1.537 billion, and 1.949 billion respectively [2] - Another subsidiary, Taizhou Danrui Biotechnology Co., Ltd., had external guarantees of 531 million and 547 million in 2019 and 2020 respectively [2] Group 2: Related Party Transactions - Nanjing Xinjie failed to disclose fund occupation by its controlling shareholder, Sanpower Group, which involved indirect payments totaling 492 million in July and August 2017 [3] - Sanpower Group did not submit a list of related parties as required, leading to undisclosed transactions totaling 193.35 million with various companies in 2017 and 2018 [4] Group 3: Regulatory Actions - The Shanghai Stock Exchange issued public reprimands to Nanjing Xinjie, Sanpower Group, and several key executives, including the actual controller and former chairmen [4] - The China Securities Regulatory Commission (CSRC) imposed fines of 4 million on Sanpower Group and 2 million on the actual controller, along with a 10-year market ban for the controller [6] Group 4: Company Background - Nanjing Xinjie, established in August 1952 and listed in 1993, is a "Chinese Time-honored Brand" and primarily operates in modern commerce, health care, and biomedical sectors, with major revenue from health care [5]

Core Viewpoint - Nanjing Xinjiekou Department Store Co., Ltd. (Nanjing Xinjie, 600682) faced disciplinary actions from the Shanghai Stock Exchange due to failures in timely reviewing and disclosing external guarantee matters, leading to penalties for three chairmen [1][4] Group 1: External Guarantees - Nanjing Xinjie’s subsidiary, Nanjing Xinjie Real Estate Development Co., Ltd., had external guarantees from 2018 to 2021 amounting to 20.95 billion, 13.76 billion, 15.37 billion, and 19.49 billion respectively [2] - Another subsidiary, Taizhou Danrui Biotechnology Co., Ltd., had external guarantees of 5.31 billion and 5.47 billion in 2019 and 2020 respectively [2] Group 2: Related Party Transactions - Nanjing Xinjie failed to disclose fund occupation by its controlling shareholder, Sanpower Group, which involved indirect payments totaling 4.92 billion in July and August 2017 [3] - Sanpower Group did not submit a list of related parties as required, leading to undisclosed transactions totaling 193.35 million and additional transactions of 90 million and 107.5 million in 2017 and 2018 [4] Group 3: Regulatory Actions - The Shanghai Stock Exchange issued public reprimands to Nanjing Xinjie, Sanpower Group, and several executives including the actual controller and former chairmen due to the aforementioned issues [4] - The China Securities Regulatory Commission (CSRC) imposed fines of 4 million on Sanpower Group and 2 million on the actual controller, along with a 10-year market ban for the controller [6] Group 4: Company Background - Nanjing Xinjie, established in August 1952 and listed in 1993, is a "Chinese Time-honored Brand" and primarily operates in modern commerce, health care, and biomedical sectors, with major revenue from the health care industry [5]

Group 1 - A new company named Shijiazhuang Yian Intelligent Technology Co., Ltd. has been established with a registered capital of 100,000 RMB [1] - The legal representative of the company is Niu Jiangang [1] - The company's business scope includes various services related to artificial intelligence, computer hardware and software, health management, and medical devices [1] Group 2 - The company is involved in the development of AI application software and system integration services [1] - It also provides services in IoT technology, health consulting, and elderly care [1] - The company is authorized to produce and sell first and second-class medical devices, subject to regulatory approval [1]

Core Viewpoint - The company held its 2024 Annual General Meeting, discussing various operational and financial aspects, including a slight increase in revenue but a significant decrease in net profit, alongside strategic plans for future growth in various sectors [1][21][24]. Group 1: Meeting Details - The 2024 Annual General Meeting is scheduled for May 21, 2025, at 13:30 in Nanjing [1]. - The meeting will include both on-site and online voting methods [4]. - Legal opinions will be provided by Jiangsu Taihe Law Firm during the meeting [3][4]. Group 2: Financial Performance - The company achieved an operating revenue of 6.7 billion yuan, a year-on-year increase of 1.98%, with the main business revenue accounting for 95.91% [5][21]. - The net profit attributable to shareholders was 230 million yuan, a decrease of 46.10% compared to the previous year [21][24]. - The total assets of the company reached 26.225 billion yuan, with total liabilities of 7.132 billion yuan [23]. Group 3: Business Segments - The main business sectors include commercial retail, hospitality, health and elderly care, professional technical services, pharmaceutical manufacturing, and medical services [5][21]. - The commercial sector reported a revenue of 412 million yuan, down 11.27% year-on-year [22]. - The health and elderly care sector generated 2.128 billion yuan, with a slight decrease of 0.11% [22]. Group 4: Strategic Initiatives - The company is focusing on enhancing its core business capabilities and expanding its market presence in health and elderly care services, as well as in the biomedical sector [26][29]. - Plans include upgrading retail spaces and introducing new brands to improve customer experience [29]. - The company aims to retain undistributed profits for future investments in market expansion and R&D [31]. Group 5: Governance and Compliance - The board of directors held eight meetings during the reporting period, ensuring compliance with legal and regulatory requirements [9][12]. - The independent directors actively participated in decision-making and oversight, contributing to the company's stable development [14][15]. - The company has established a robust internal control system to manage operational risks effectively [16][20]. Group 6: Future Outlook - The company anticipates continued growth in the health and elderly care market, driven by an aging population and increasing consumer demand [25][27]. - The biomedical sector is expected to expand significantly, supported by government policies promoting stem cell technology and clinical applications [26][28]. - The retail business is undergoing transformation to adapt to market changes and consumer preferences, aiming for sustainable growth [29][31].